Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Savara Inc. (SVRA)

1.44   -0.01 (-0.69%) 11-25 13:00
Open: 1.44 Pre. Close: 1.45
High: 1.47 Low: 1.42
Volume: 21,383 Market Cap: 164(M)

Technical analysis

as of: 2022-11-25 2:00:42 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.71     One year: 2
Support: Support1: 1.22    Support2: 1.08
Resistance: Resistance1: 1.47    Resistance2: 1.71
Pivot: 1.27
Moving Average: MA(5): 1.42     MA(20): 1.25
MA(100): 1.47     MA(250): 1.34
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 91.4     %D(3): 91
RSI: RSI(14): 66.8
52-week: High: 1.9  Low: 1.01
Average Vol(K): 3-Month: 97 (K)  10-Days: 62 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SVRA ] has closed below upper band by 16.5%. Bollinger Bands are 65.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.46 - 1.47 1.47 - 1.48
Low: 1.38 - 1.39 1.39 - 1.4
Close: 1.44 - 1.45 1.45 - 1.46

Company Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Headline News

Tue, 22 Nov 2022
Board Member of Savara Purchased $68K In Stock - Savara (NASDAQ:SVRA) - Benzinga

Mon, 21 Nov 2022
Insider Buying: Savara Inc (NASDAQ:SVRA) Director Buys 8900 Shares of Stock - MarketBeat

Wed, 16 Nov 2022
HC Wainwright Weighs in on Savara Inc's FY2022 Earnings (NASDAQ:SVRA) - MarketBeat

Mon, 14 Nov 2022
Venrock Healthcare Takes Significant Position in SVRA / Savara - Nasdaq

Thu, 10 Nov 2022
Savara GAAP EPS of -$0.07 in-line (NASDAQ:SVRA) - Seeking Alpha

Thu, 03 Nov 2022
SpeedTour descends on COTA with Trans Am, SVRA, FR Americas and F4 U.S. championship finales - RACER

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 114 (M)
Shares Float 46 (M)
% Held by Insiders 1.9 (%)
% Held by Institutions 71.9 (%)
Shares Short 536 (K)
Shares Short P.Month 553 (K)

Stock Financials

EPS -0.27
EPS Est Next Qtl -0.51
EPS Est This Year -2.35
EPS Est Next Year -1.87
Book Value (p.s.) 1.01
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -14.2
Return on Equity (ttm) -28.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.26
Sales Per Share 0
EBITDA (p.s.) -0.34
Qtrly Earnings Growth 0
Operating Cash Flow -35 (M)
Levered Free Cash Flow -22 (M)

Stock Valuations

PE Ratio -5.36
PEG Ratio 0
Price to Book value 1.41
Price to Sales 0
Price to Cash Flow -4.66

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2017-04-27
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.